Illumina Analysts Question Grail Deal's Commercial Opportunity, Hefty Price Tag
Illumina, Inc. (NASDAQ: ILMN) announced Monday a deal to buy privately held Grail, which focuses on early detection of multiple cancers, for $8 billion in cash and stock.